β-hydroxy-β-methylbutyrate-enriched Nutritional Supplements for Obesity Adults

Obesity Clinical Trial

Official title:

β-hydroxy-β-methylbutyrate-enriched Nutritional Supplements for Obesity Adults During Weight Loss: a Randomized Double-blind Placebo-controlled Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04953936
• Other study ID #: 2021(202)
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 20, 2021
• Est. completion date: December 31, 2021

Study information

• Verified date: September 2021
• Source: West China Hospital
• Contact: Yuxaing Liang
• Phone: 0086-13982250862
• Email: yx45liang[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the effectiveness and safety of HMB-enriched nutritional supplements for improving muscle mass and muscle function in Chinese adults with obesity during the weight loss process using calorie restriction.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 72
• Est. completion date: December 31, 2021
• Est. primary completion date: October 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Men and women aged 30-50 years

2. Currently having obesity defined by body mass index (BMI) = 28 kg/m2 (based on measured body weight and height at booking, using validated scales)

3. Having an intention to lost weight via caloric restriction

4. Apparently healthy and able to walk independently

5. Able to eat independently to meet their energy needs

6. Without significant body weight change in the last 6 month (less than 5% change in body weight)

7. Having sedentary habit defined by Sedentary Behavior Research Network

8. Able to collaborate with the research staff.

Exclusion Criteria:

1. Having a history of intolerance to enteral nutrition, food (e.g., lactose intolerance), or being allergic to the components of our HMB-enriched nutritional supplements (e.g., soy or corn);

2. Having any implants (e.g., pacemakers);

3. Current use of other nutritional supplements or drugs that may have an impact on the effectiveness of the intervention (e.g., glucocorticoids, antineoplastic drugs, antituberculosis drugs, sedatives, antipsychotics, muscle relaxants, monoamine oxidase inhibitors, antibiotics) within 3 months prior to enrollment;

4. Secondary obesity caused by diseases (e.g., hypothalamic diseases and hypercortisolism) or drugs (e.g. glucocorticoids, insulin, tricyclic antidepressants);

5. Clinically visible edema;

6. Trauma, surgery, hospitalization, fall, or fracture within 6 months prior to enrollment;

7. Pregnancy, having pregnancy plans, or lactation;

8. Individuals who are participating in other clinical trials; any acute illness (e.g., acute infection, myocardial infarction, arrhythmia, myocarditis, appendicitis, etc.);

9. Swallowing disorders; abnormal thyroid function (including hyperthyroidism and hypothyroidism);

10. Having a history of diabetes, respiratory diseases, cardiovascular diseases, uncontrolled hypertension, kidney diseases, digestive system diseases, renal insufficiency, mental illness, neurological diseases, hematologic diseases, liver diseases (except for fatty liver), chronic infection (e.g., tuberculosis), immune system diseases, joint disorders, any type of tumor;

11. Alcohol consumption over two standard alcoholic beverages (20 g of alcohol/day);

12. Difficulty to comply with the study protocol;

13. Other conditions that indicate the individuals are inappropriate for participation in this study.

Related Conditions & MeSH terms

• Obesity

Intervention

Dietary Supplement:
• HMB-enriched Nutritional Supplements
The participants will receive oral HMB-enriched nutritional supplements (65 g, once daily), which include soybean isolate protein, flaxseed oil powder, yam powder, whey protein, oligomeric isomaltose powder, cocoa powder, medium-chain fatty acid powder, calcium beta-hydroxy-beta-methylbutyrate, sunflower seed oil powder, L-glutamine, wheat germ powder, membrane isolated casein, wheat oligopeptide, konjac flour, vitamin E, vitamin D, stevioside, edible flavors.
• Placebo
Placebo (maltodextrin 65 g once daily) with the same package as the intervention.

Behavioral:
• Caloric Restrition Diet
Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies

Locations

Country	Name	City	State
China	West China Hospital,Sichuan University	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The mean change in whole-body skeletal muscle mass (SMM)	The whole-body skeletal muscle mass (SMM)	12 weeks
Secondary	The mean change in appendicular skeletal muscle mass (ASMM)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
Secondary	The mean change in trunk skeletal muscle mass (TSMM)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
Secondary	The mean change in total body fat mass (BFM)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
Secondary	The mean change in total appendicular body fat mass (ABFM)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
Secondary	The mean change in trunk body fat mass (TBFM)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
Secondary	The mean change in basal metabolic rate (BMR)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
Secondary	The mean change in phase angle (PA)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
Secondary	The mean change in body weight (BW)	These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).	12 weeks
Secondary	The mean change in handgrip strength (HGS)	A trained nurse will measure HGS using a digital handheld dynamometer (EH101; Xiangshan Inc, Guangdong, China) to the nearest 0.1 kg .	6 and 12 weeks
Secondary	The mean change in waist circumference	A trained nurse will measure waist circumference using a tape at the level midway between the lower rib margin and the iliac crest with the participant breathing out gently.	6 and 12 weeks
Secondary	The mean change in hip circumference	Hip circumference was measured as the maximum circumference over the buttocks	6 and 12 weeks
Secondary	The mean change in physical activity	It will be measured using self-reported International Physical Activity Questionnaire Short Form (IPAQ-SF).The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. Long (5 activity domains asked independently) and short (4 generic items) versions for use by either telephone or self-administered methods are available. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health related physical activity.	From the beginning to weeks 3, 6, 9, and 12.
Secondary	The mean change in the score of the sit-to-stand test	A trained nurse will perform the 30-second sit-to-stand test ,which is a classic test for measuring the performance of lower extremity muscles.	6 and 12 weeks
Secondary	The mean change in energy intake	It will be measured for all participants using the self-reported Food Frequency Questionnaire (FFQ)	From the beginning to weeks 3, 6, 9, and 12
Secondary	The mean change in lipid profiles	It will be tested using standard method.	12 weeks
Secondary	The mean change in fasting glucose	It will be tested using standard method.	12 weeks
Secondary	The mean change in fasting insulin	It will be tested using standard method.	12 weeks
Secondary	The mean change in HOMA-IR	It will be tested using standard method.	12 weeks
Secondary	The mean change in albumin	It will be tested using standard method.	12 weeks